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Abstract: Targeting of the vascular endothelium compartment explains, in part, the   therapeutic 
efficacy of the nonselective β-adrenergic antagonist propranolol against common endothelial 
tumors such as hemangiomas. In vitro, the antiangiogenic biological activity of propranolol 
was shown to inhibit human brain microvascular endothelial cell tubulogenesis. However, 
  possible interference of propranolol with cell signaling associated with the tumoral   compartment 
remains unexplored. We therefore assessed the potency of propranolol against a pediatric brain 
  tumor-derived DAOY medulloblastoma cell model. Gene   expression of β1-, β2-, and β3-adrenergic 
receptors was confirmed in DAOY cells by semiquantitative RT-PCR. We next found that 
propranolol dose-dependently inhibited induction of the key extracellular   matrix-degrading 
and blood–brain barrier disrupting enzyme matrix   metalloproteinase-9 (MMP-9) by phorbol 
12-myristate 13-acetate (PMA). Propranolol not only inhibited   PMA-induced phosphorylation 
of the extracellular signal-regulated kinase (Erk), but also that of IkappaB (IκB), preventing the 
IκB phosphorylation which is a prerequisite for IκB   degradation.   Propranolol inhibition of IκB 
phosphorylation was shown to occur with   optimal efficacy at 30 µM. Although propranolol, at 
up to 100 µM, did not affect cell viability, it potentiated   PMA-mediated   signaling that ultimately 
led to diminished phosphorylation of Akt. The anti-Erk and anti-Akt   phosphorylation effects 
are both suggestive of antiproliferative and antisurvival signaling, respectively. Our data are 
therefore indicative of a pharmacological role for propranolol against β-adrenergic receptor 
signaling functions involving the nuclear   factor-kappaB-mediated regulation of MMP-9.
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Introduction
The expression of matrix metalloproteinase-9 (MMP-9) is significantly increased 
  during tumor progression and is considered as a major contributor to the opening of 
the   blood–brain barrier (BBB).1 Although human brain microvascular endothelial 
cells (HBMEC) play an essential role as structural and functional components of 
the BBB, it is unclear whether MMP-9 that causes its disruption originates from the 
vascular or the tumoral compartment. Recent evidence from adenoviral-mediated 
MMP-9   downregulation demonstrated a key role for MMP-9 in endothelial cell 
network   organization as human dermal microvascular endothelial cell migration and 
  capillary-like tube formation were reduced in cell wounding and spheroid   migration 
assays.2 Aside from involvement in angiogenesis, MMP-9 is also known to be required 
for tumor vasculogenesis,3 an alternative pathway for neovascularization that is 
increasingly being found in a variety of states characterized by vascular growth such 
as hemangioma.4 In the latter, MMP-9 was among the increased hypoxia-induced OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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mediators characterizing the stem/progenitor cells in children 
with hemangioma.5
Any therapeutic strategies leading to specific   targeting 
of MMP-9 is therefore likely to be of utility in treating 
  common endothelial tumors such as hemangiomas of infancy. 
Accordingly, therapeutic targeting of β-adrenergic receptor 
functions with propranolol was found to efficiently inhibit 
neovascularization during the proliferative phase of infantile 
hemangioma.6,7 The exact mechanism and signaling pathways 
involved in this inhibition of MMP-9 expression still remain 
undefined, and it is believed that marrow-derived endothelial 
progenitor cells may be partly involved.5 While recent   studies 
delineated a unique brain endothelial phenotype in which 
MMP-9 secretion by HBMEC was increased upon   treatment 
with the tumor-promoting agent phorbol 12-myristate 
13-acetate,8–10 the effects of propranolol and the   contribution 
of β-adrenergic receptor function to the regulation of 
MMP-9 secretion by the tumor compartment itself has received 
little attention. In fact, we have shown that MMP-9 is secreted 
by numerous cell types and that its presence is often indica-
tive of an invasive phenotype during tumor   development.8,11–14 
Leakiness of the vascular endothelium is among the best known 
of the deleterious brain tumor-  associated effects.15,16 Whether 
any β-adrenergic receptor-mediated functions are involved in 
such events is unknown.
In this study, we used the pediatric brain tumor-derived 
DAOY cell line model to assess the potential contributions 
of β-adrenergic receptor functions regulating MMP-9 secre-
tion. Propranolol’s pharmacological effects were tested and 
we provide molecular evidence showing that inhibition of 
nuclear factor-kappaB (NF-κB)-mediated brain tumor signal-
ing specifically reduces the secretion of MMP-9.
Material and methods
Materials
Propranolol, sodium dodecylsulfate (SDS) and bovine serum 
albumin (BSA) were purchased from Sigma (Oakville, ON, 
Canada). Electrophoresis reagents were purchased from Bio-
Rad (Mississauga, ON, Canada). The enhanced chemilumines-
cence (ECL) reagents were from Perkin Elmer (Waltham, MA, 
USA). Micro bicinchoninic acid protein assay reagents were 
from Pierce (Rockford, IL, USA). The polyclonal antibodies 
against phospho-ERK, Akt and phospho-Akt were purchased 
from Cell Signalling (Danvers, MA, USA), the polyclonal 
anti-ERK antibody was from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). The monoclonal antibody against 
GAPDH was from Advanced Immunochemical Inc. (Long 
Beach, CA). Horseradish peroxidase-conjugated donkey 
antirabbit and antimouse IgG secondary antibodies were from 
Jackson ImmunoResearch Laboratories (West Grove, PA). All 
other reagents were from Sigma-Aldrich Canada.
cell culture
The human DAOY medulloblastoma cell line was purchased 
from American Type Culture Collection and was maintained 
in Eagle’s Minimum Essential Medium containing 10% (v/v) 
calf serum (HyClone Laboratories, Logan, UT), 2 mM 
  glutamine, 100 units/mL penicillin and 100 mg/mL streptomycin. 
Cells were incubated at 37°C, with 95% air and 5% CO2.
cDnA synthesis and real-time 
quantitative rT-Pcr
Total RNA was extracted from cultured DAOY cells using 
TRIzol reagent. For cDNA synthesis, ∼1 µg total RNA was 
reverse-transcribed into cDNA using an oligo dT primer 
and the iScript reverse transcriptase cDNA synthesis kit 
(Bio-Rad, Mississauga, ON, Canada). cDNA was stored at 
–20°C for PCR (Applied Biosystems Inc, Foster City, CA). 
Human primers for β1- (QT00204309), β2- (QT00200011), 
and β3- (QT00200004) adrenergic receptors and for 
Peptidylprolyl isomerase A (PPIA, QT01866137) were 
from QIAGEN. Semi-quantitative RT-PCR analysis was 
performed starting with 1 µg cDNA, followed by specific 
gene product amplification with the One-Step RT-PCR Kit 
(Invitrogen, Burlington, ON, Canada). PCR conditions 
were optimized so that the gene products were examined 
at the exponential phase of their amplification and the 
products were resolved on 1.8% agarose gels containing 
1 µg/mL ethidium bromide.
gelatin zymography
Gelatin zymography was used to assess the extent of proMMP-2 
and proMMP-9 activity as previously described.10 Briefly, an 
aliquot (20 µL) of the culture medium was subjected to SDS– 
polyacrylamide gel electrophoresis (PAGE) in a gel containing 
0.1 mg/mL gelatin. The gels were then incubated in 2.5% Triton 
X-100 and rinsed in nanopure distilled H2O. Gels were further 
incubated at 37°C for 20 hours in 20 mM NaCl, 5 mM CaCl2, 
0.02% Brij-35, 50 mM Tris-HCl buffer, pH 7.6, then stained 
with 0.1% Coomassie Brilliant blue R-250 and destained in 
10% acetic acid, 30% methanol in H2O. Gelatinolytic activity 
was detected as unstained bands on a blue background.
immunoblotting procedures
Proteins from control and treated cells were separated 
by SDS–PAGE. After electrophoresis, proteins were OncoTargets and Therapy 2010:3
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Figure 1 gene expression analysis of β-adrenergic receptor expression in DAOY 
medulloblastoma cells. Total rnA was extracted from medulloblastoma-derived 
DAOY cells and semi-quantitative rT-Pcr performed as described in the Methods 
section. cDNA amplicons were resolved on an agarose gel in order to confirm a 
single amplification product.
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  electrotransferred to polyvinylidene difluoride membranes 
which were then blocked for 1 hour at room temperature 
with 5% nonfat dry milk in Tris-buffered saline (150 mM 
NaCl, 20 mM Tris–HCl, pH 7.5) containing 0.3%   Tween-20 
(TBST). Membranes were further washed in TBST and incu-
bated with the primary antibodies (1/1000 dilution) in TBST 
containing 3% bovine serum albumin, followed by a 1-hour 
incubation with horseradish peroxidase-conjugated antirabbit 
or antimouse IgG (1/2,500 dilution) in TBST containing 5% 
nonfat dry milk. Immunoreactive material was visualized by 
enhanced chemiluminescence (Amersham Biosciences, Baie 
d’Urfé, QC, Canada).
cytotoxicity and cell proliferation assays
To assess the effect of propranolol on DAOY cell viability, 
the release of lactate dehydrogenase (LDH) upon damage of 
the plasma membrane was analyzed in the same condition 
media that was used for gelatin zymography. LDH activity 
was measured at 30°C by a continuous optical test based on 
the extinction change of pyridine nucleotide at 340 nm as 
described by the manufacturer’s instructions (Promega). The 
cleavage of the tetrazolium salt WST-1 {4-[3-(4-iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate} 
by mitochondrial dehydrogenases (Roche Diagnostics, Laval, 
QC, Canada) was also used to assess cell proliferation.
Results
expression of β-adrenergic receptor 
transcripts in medulloblastoma-derived 
DAOY cells
β1-, β2-, and β3-adrenergic receptor gene expression was first 
assessed for medulloblastoma-derived DAOY cells from which 
total RNA had been extracted. The design of primers enabled 
measurement of the expression levels for each of the individual 
human β-adrenergic genes and of the house keeping gene PPIA. 
This was validated by visualization of a single cDNA amplicon 
product obtained from total RNA by semi-quantitative RT-PCR 
on an agarose gel (Figure 1). This confirms that β-adrenergic 
receptors are expressed in DAOY cells.
Propranolol inhibits phorbol 12-myristate 
13-acetate (PMA)-induced secretion of 
MMP-9 in DAOY medulloblastoma cells
DAOY cells were serum-starved and treated for 18 hours with 
various doses of propranolol in the presence or absence of a 
fixed (1 µM) PMA concentration (Figure 2A); other cells were 
treated with various doses of PMA in the presence or absence 
of 30 µM propranolol (Figure 2B). The conditioned media 
were harvested to measure the levels of MMP-9 by gelatin 
zymography. While MMP-9 activity was undetectable under 
basal conditions (Figure 2A, upper panel), it was significantly 
increased in PMA-treated cells (Figure 2A, lower panel). 
When DAOY were treated with combined PMA and propra-
nolol, MMP-9 was dose-dependently inhibited with an IC50 of 
∼3.1 µM propranolol (Figure 2C). Maximal MMP-9 secretion 
was achieved with PMA at 1 µM (Figure 2B, upper panel). 
This induction was significantly inhibited in the presence of 
30 µM propranolol (Figure 2D). Collectively, these results sug-
gest that propranolol selectively inhibits MMP-9 in response 
to carcinogenic-promoting conditions.
Propranolol reverses  
PMA-mediated iκB decrease
Among MMP-9 expression regulators, the nuclear factor-
kappaB (NF-κB) signaling pathway has been demonstrated 
to link cancer to inflammatory diseases.17 We therefore 
first assessed whether this signaling was activated upon 
PMA treatment and whether it was reflected in IkappaB 
(IκB) degradation. Cells were treated with 1 µM PMA for 
18 hours, lysates were isolated and IκB expression was 
assessed through Western blotting. PMA signaling led to 
decreased IκB expression (Figure 3, black bar). Increasing 
doses of propranolol were found to dose-dependently reverse 
the PMA-mediated decrease of IκB, suggesting possible 
signaling interference by propranolol of IκB, whose phos-
phorylation is essential for its degradation.18
Propranolol inhibits PMA-induced iκB 
phosphorylation that leads  
to iκB degradation
PMA-mediated phosphorylation of IκB was next assessed in 
order to show whether this explains the subsequent decrease 
in IκB expression. DAOY cells were treated for 45 minutes 
with 1 µM PMA following preincubation with either vehicle 
or 30 µM propranolol. Preincubation with vehicle followed 
by PMA treatment rapidly led to IκB phosphorylation and to 
a concomitant decrease in IκB (Figure 4A, left panel). When OncoTargets and Therapy 2010:3
0
20
40
60
80
100
0
0 0.01
Vehicle
Propranolol
Vehicle Vehicle
PMA
AB
CD
0 0.01 0.03 0.1 0.3 1
Propranolol
PMA (µM)
PMA (µM)
0.03 0.1 0.3 1
5
10
15
20
25
Propranolol (µM)
Propranolol (µM)
PMA
M
M
P
-
9
 
a
c
t
i
v
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
M
M
P
-
9
 
a
c
t
i
v
i
t
y
 
(
x
-
f
o
l
d
 
o
v
e
r
 
b
a
s
a
l
)
0131 03 01 00
0131 03 0 100
Figure 2 Propranolol inhibits PMA-induced matrix metalloproteinase-9 (MMP-9) secretion in DAOY medulloblastoma cells. Medulloblastoma-derived DAOY cells were 
serum-starved in the presence of various concentrations of propranolol in combination with vehicle or 1 µM PMA for 18 hours (A), or in the presence of various 
concentrations of PMA in combination with vehicle or 30 µM propranolol for 18 hours (B). scanning densitometry was used to quantify the extent of proMMP-9 gelatinolytic 
activity for each set of data (C, D). Data shown is representative of two independent experiments.
Abbreviation: PMA, phorbol 12-myristate 13-acetate.
0
00 0131 03 0 Propranolol (µM)
I
k
B
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
PMA +++++
01 31 03 0 Propranolol (µM)
PMA
IKB
GAPDH
+ −+ +++
−+
20
40
60
80
100
120 B
A
Figure 3 Propranolol reverses PMA-mediated iκB degradation. Medulloblastoma-
derived DAOY cells were serum-starved in the presence of various concentrations 
of propranolol in combination with vehicle or1 µM PMA for 18 hours. A) Lysates 
were  isolated,  electrophoresed  via  sodium  dodecylsulfate–polyacrylamide  gel 
electrophoresis and immunodetection of iκB and gAPDh proteins was performed 
as described in the Methods section. B) Quantification was performed by scanning 
densitometry  of  the  autoradiograms.  Data  were  expressed  as  the  percent  (%) 
expression of untreated basal conditions.
Abbreviation: PMA, phorbol 12-myristate 13-acetate.
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DAOY cells were preincubated with propranolol, PMA was 
unable to induce IκB phosphorylation and,   consequently, IκB 
protein levels remained unchanged throughout the 45-minute 
treatment (Figure 4A, right panel). The   corresponding 
levels of phosphorylated IκB (Figure 4B) and of total 
IκB (Figure 4C) expression were quantified by scanning 
densitometry.
Propranolol inhibits PMA-induced 
phosphorylation of erk, and potentiates 
PMA-mediated Akt dephosphorylation
Alternative signaling pathways known to be triggered by 
PMA include the Erk pathway as well as the Akt   pathway.19,20 
Although Erk/Akt signaling cross talks are well documented, 
the former is involved in cell proliferation21 while the   latter 
regulates cell survival.22 Pharmacological β-adrenergic block-
ade strategies specifically aimed at targeting these two signal-
ing pathways may provide additional tools to reduce DAOY 
cell proliferation and/or survival. DAOY cells were therefore 
treated under conditions similar to those shown in Figure 4 
(ie, stimulated for 45 minutes with 1 µM PMA following 
preincubation with either vehicle or 30 µM   propranolol). 
We found that preincubation with vehicle followed by PMA 
treatment led to increased Erk phosphorylation with no 
effect on Akt phosphorylation status (Figure 5A, left panel). 
When DAOY cells were   preincubated with propranolol, Erk 
phosphorylation by PMA was significantly reduced, while 
phosphorylation levels of Akt decreased as quickly as 10 min-
utes following PMA stimulation (Figure 5A, right panel). 
The corresponding ratios of phosphorylated Erk/total Erk 
(Figure 5B) and of phosphorylated Akt/total Akt (Figure 5C) 
were quantified by scanning densitometry. Cell proliferation OncoTargets and Therapy 2010:3
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Figure 4 Propranolol inhibits PMA-induced iκB phosphorylation that leads to iκB degradation. A) Medulloblastoma-derived DAOY cells were serum-starved for 30 minutes 
in the presence of vehicle or 30 µM propranolol. cells were then incubated for the indicated time with vehicle or 1 µM PMA. Lysates were isolated, electrophoresed via 
sodium dodecylsulfate–polyacrylamide gel electrophoresis and immunodetection of phosphorylated iκB (P-iκB), iκB, and of gAPDh proteins was performed as described in 
the Methods section. B, C) Quantification was performed by scanning densitometry of the autoradiograms. Data were expressed as x-fold induction over basal untreated 
cells for P-iκB, and as the percent (%) expression of untreated basal conditions for iκB.
Abbreviation: PMA, phorbol 12-myristate 13-acetate.
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Figure 5 Propranolol inhibits PMA-induced phosphorylation of erk, and potentiates PMA-mediated Akt phosphorylation. A) Medulloblastoma-derived DAOY cells were 
serum-starved for 30 minutes in the presence of vehicle or 30 µM propranolol. cells were then incubated for the indicated time with vehicle or 1 µM PMA. Lysates were 
isolated, electrophoresed via sodium dodecylsulfate–polyacrylamide gel electrophoresis and immunodetection of phosphorylated erk (P-erk), erk, phosphorylated Akt 
(P-Akt), and of Akt proteins was performed as described in the Methods section. B, C) Quantification was performed by scanning densitometry of the autoradiograms. Data 
were expressed as x-fold induction over basal untreated cells for P-erk/erk, and as the percent (%) expression of untreated basal conditions for P-Akt/Akt.
Abbreviation: PMA, phorbol 12-myristate 13-acetate.
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Figure 6 Propranolol inhibits PMA-induced cell proliferation but not cell survival. 
A) Medulloblastoma-derived DAOY cells were treated as described in Figure 2 and 
left to grow for 48 hours. cell proliferation assay was performed as described in 
the Methods section. B) cell death was assessed through the release of LDh into 
the conditioned media and assessed as described in the Methods section of serum-
starved DAOY cells treated with vehicle (white bar), 50 µM etoposide (grey bar), or 
100 µM propranolol (black bar). 
Abbreviation: PMA, phorbol 12-myristate 13-acetate.
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assays confirmed the antiproliferative effect of propranolol 
(  Figure 6A), while no cell death was induced at up to 100 µM 
  propranolol (  Figure 6B). Collectively, this experimental 
evidence suggests that β-adrenergic blockade rather exerts 
strong antiproliferative effects combining the converging 
signaling originating from Erk/Akt pathways.
Discussion
Propranolol is a nonselective β-adrenergic antagonist that 
crosses the BBB and which is widely used clinically for vari-
ous conditions including hypertension, anxiety and excessive 
sympathetic responses that often characterize patients during 
the perioperative period.23 Clinical benefits have been observed 
in combination with COX-2 inhibitors in postoperation cancer 
patients, in whom perioperative treatment resulted in improved 
immune competence and in reduced risk of tumor metastasis.24 
It was therefore inferred that blockade of β-adrenergic recep-
tor functions would affect tumor development, an effect that 
was confirmed by the inhibition of experimentally induced 
pulmonary adenocarcinoma development.25 The contribution 
of β-adrenergic receptor functions to tumorigenesis was also 
reflected by the suggested antiangiogenic effects of β-blockers 
on a tumor-associated endothelial cell model. As such, evidence 
for increased expression of β2-adrenergic receptors in the brain 
tumor-derived vascular compartment was demonstrated, and 
adrenergic blockade with propranolol resulted in the inhibition 
of HBMEC tubulogenesis.26 Targeting brain tumor-associated 
endothelial cell functions with β-blockers, as part of cancer 
treatments, may therefore become an appealing prospect to 
be further investigated.
To date, no human clinical study has documented 
the specific chemotherapeutic effect of propranolol in 
  anticancer therapy. In vivo clinical data will ultimately 
provide definitive proof as to the therapeutic efficacy of 
propranolol in anticancer treatments, and may benefit from 
our in vitro demonstration and elucidation of propranolol’s 
molecular mechanism of action. Among the strongest evi-
dence, and perhaps the best in vivo study that supports our 
current data, is the demonstration that MMP-9 and the pro-
angiogenic factor VEGF are both inhibited by propranolol 
in nasopharyngeal carcinoma tumor cells.27 Several other in 
vivo approaches have also shed light on the chemopreven-
tive actions of propranolol in reducing pancreatic ductal 
adenocarcinoma growth in animal models28 and in reducing 
metastatic development of PC-3 prostate cancer in nude 
mice.29 Such published data strongly suggest a potent anti-
cancer action in line with those we infer in this study using 
a DAOY pediatric brain tumor-derived cellular model.
One major implication of our study relates to the docu-
mented relationship between inflammation and   cancer. Increas-
ing evidence suggests that the inflammatory microenvironment 
in and around tumors is an   indispensable   participant in the 
neoplastic process.30 NF-κB plays an   important role in the 
regulation of inflammatory responses and where NF-κB 
signaling can be activated by diverse stimuli including 
proinflammatory cytokines, infectious agents and cellular 
stresses.31 It may therefore be appealing in both the prevention 
and treatment of brain cancers to target NF-κB signaling that 
regulates, in part, MMP-9 expression.   Accordingly, targeting 
capacity of several pharmacological agents has led to inhibi-
tion of MMP-9; these agents include numerous nutraceutical 
molecules. Among these,   sulforaphane,8,32 epigallocatechin-
gallate,14,33,34 curcumin,35,36 resveratrol,37,38 proanthocyanidins39 
and lycopene40 have all been proved to inhibit MMP-9 expres-
sion/secretion. More interestingly, all of the above-mentioned 
diet-derived molecules also abrogated the NF-κB signaling 
pathway which regulates MMP-9 expression.41
PMA-induced IκB phosphorylation and subsequent 
degradation, which together results in the release of NF-κB 
p65 and p50 subunits followed by their nuclear   translocation, 
subsequently regulates MMP-9 transcription.42 We show 
that inhibition of IκB phosphorylation by propranolol 
accordingly results in diminished downstream expression 
of MMP-9 expression. Finally, our data also provide support 
to the Erk/Akt signaling crosstalk regulating cell proliferation. 
It is well documented that Erk activation is required for cell 
proliferation to proceed.43 Furthermore, natural biological 
regulation of Erk nuclear localization has been demonstrated OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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to regulate cell proliferation, while overactivation of Akt has 
been shown to prevent the nuclear translocation of Erk by 
stabilizing endogenous PEA15, resulting in cell proliferation 
restriction.44 Inhibition of such signaling crosstalk, as we 
observe for the effect of propranolol, may therefore be viewed 
as a double check-point control since propranolol not only 
inhibits Erk phosphorylation status, but would also possibly 
prevent Akt-mediated Erk nuclear translocation, the overall 
effect of which will result in blocking cell proliferation, in 
agreement with Figure 6A.
We have previously reported that medulloblastoma-derived 
cancer stem cells possessed increased MMP-9 expression in 
neurosphere cultures,13 and that members of the low-density 
lipoprotein receptor-related proteins, which also exhibit impor-
tant functions in MMP-9 recycling,45,46   provided a differential 
molecular signature between parental and CD133+ DAOY 
medulloblastoma cells.47 Increased MMP-9 expression was 
also associated with colospheres derived from colon cancer 
cultures.48 Collectively, these data suggest that cancer stem 
cell targeted strategies involving MMP-9   expression may pos-
sibly be envisioned. Whether β-adrenergic blockade would be 
involved remains to be   determined. In support of our current 
data with brain tumor cells, β2-adrenergic antagonists sup-
pressed   pancreatic   cancer cell invasion by inhibiting NF-κB and 
MMP-9   expression,49 while MMP-9 levels were decreased upon 
β1- and β2-adrenoceptor blockade.50 In summary, our data are 
indicative of a role for propranolol against   carcinogen-mediated 
signaling that leads to the secretion of the BBB disruptor enzyme 
MMP-9. Our results also   illuminate the alternative roles that 
excessive MMP-9 expression may play in inflammatory diseases 
and in inflammation associated with tumor development.
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